Skip to main content

Table 4 Change from baseline in electrocardiogram categorical measures

From: A phase 3, long-term, open-label safety study of Galcanezumab in patients with migraine

Category Post Baseline Galcanezumab 120 mg Galcanezumab 240 mg
N n (%) N n (%)
Heart rate <  50 bpm and decrease ≥15 117 1 (0.85) 131 1 (0.76)
>  100 bpm and increase ≥15 119 1 (0.84) 131 0
PR interval <  120 msec 117 3 (2.56) 127 1 (0.79)
≥ 220 msec 119 0 130 0
QRS interval <  60 msec 120 0 131 0
≥120 msec 118 0 131 1 (0.76)
QTcF <  330 msec for males, < 340 msec for females 118 0 130 0
> 450 msec for males; > 470 msec for females 118 2 (1.69) 130 1 (0.77)
Potentially clinically significant:     
> 500 msec 118 0 130 0
Increase > 30 msec 118 2 (1.69) 130 4 (3.08)
Increase > 60 msec 118 0 130 0
  1. bpm beats per minute, PR pulse rate, QTcF QT interval adjusted for heart rate using Fridericia’s correction